share_log

和黃醫藥：自願性公告－會議通知：和黃醫藥將於2024年7月9日介紹最新研發進展

HUTCHMED: VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

Hong Kong Stock Exchange ·  Jun 24 17:36
Summary by Futu AI
和黃醫藥（中國）有限公司（「和黃醫藥」或「HUTCHMED」）將於2024年7月9日在上海舉辦線下及線上會議，分享其最新研發進展。會議將由高級管理團隊主持，介紹公司的研發策略和願景，並將重點報告包括索樂匹尼布、索凡替尼和HMPL-306等候選藥物的臨床研究進展。線下會議將於香港時間下午3時至5時舉行，並提供中文（普通話）直播。英文場次的網絡會議則安排於當日晚上8時30分開始，預計持續2小時。投資者可於會議開始前訪問公司網站下載所需軟件以收聽網絡直播，會議結束後90天內亦可在網站上收聽重播。和黃醫藥是一家專注於癌症和免疫性疾病治療藥物的生物醫藥公司，已有三款藥物在中國上市，其中一款亦在美國上市。
和黃醫藥（中國）有限公司（「和黃醫藥」或「HUTCHMED」）將於2024年7月9日在上海舉辦線下及線上會議，分享其最新研發進展。會議將由高級管理團隊主持，介紹公司的研發策略和願景，並將重點報告包括索樂匹尼布、索凡替尼和HMPL-306等候選藥物的臨床研究進展。線下會議將於香港時間下午3時至5時舉行，並提供中文（普通話）直播。英文場次的網絡會議則安排於當日晚上8時30分開始，預計持續2小時。投資者可於會議開始前訪問公司網站下載所需軟件以收聽網絡直播，會議結束後90天內亦可在網站上收聽重播。和黃醫藥是一家專注於癌症和免疫性疾病治療藥物的生物醫藥公司，已有三款藥物在中國上市，其中一款亦在美國上市。
HUTCHMED (China) Limited ("HUTCHMED") will hold offline and online meetings on July 9, 2024 in Shanghai to share its latest research and development progress. The meeting will be hosted by senior management, introducing the company's R&D strategy and vision, and highlighting the clinical research progress of candidate drugs including surufatinib, savolitinib and HMPL-306. The offline meeting will be held from 3 p.m. to 5 p.m. Hong Kong time and offer live streaming in Chinese (Mandarin). The English webcast will start at 8:30 p.m. on the same day and is expected to last for 2 hours. Investors can visit the company's website before the meeting to download the necessary software to listen to the webcast, and can also listen to the replay on the website within 90 days after the meeting. HUTCHMED is a biomedical company focused on the development of cancer and immunological disease treatments, with three drugs already on the market in China, one of which is also approved in the United States.
HUTCHMED (China) Limited ("HUTCHMED") will hold offline and online meetings on July 9, 2024 in Shanghai to share its latest research and development progress. The meeting will be hosted by senior management, introducing the company's R&D strategy and vision, and highlighting the clinical research progress of candidate drugs including surufatinib, savolitinib and HMPL-306. The offline meeting will be held from 3 p.m. to 5 p.m. Hong Kong time and offer live streaming in Chinese (Mandarin). The English webcast will start at 8:30 p.m. on the same day and is expected to last for 2 hours. Investors can visit the company's website before the meeting to download the necessary software to listen to the webcast, and can also listen to the replay on the website within 90 days after the meeting. HUTCHMED is a biomedical company focused on the development of cancer and immunological disease treatments, with three drugs already on the market in China, one of which is also approved in the United States.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.